Print

Anacor Pharmaceuticals, Inc. (ANAC) Announces Successful Completion of End-of-Phase 2 Meeting With FDA For The Treatment Of Mild-to-Moderate Atopic Dermatitis With AN2728  
2/27/2014 9:15:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) for the topical treatment of mild-to-moderate atopic dermatitis with AN2728 Ointment, 2%, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects 10% - 20% of infants and young children.

Help employers find you! Check out all the jobs and post your resume.

//-->